

Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: ASCO Clinical Practice Guideline Update

Sharon H. Giordano, Sarah Temin, Sarat Chandarlapaty, Jennie R. Crews, Francisco J. Esteva, Jeffrey J. Kirshner, Ian E. Krop, Jennifer Levinson, Nancy U. Lin, Shanu Modi, Debra A. Patt, Jane Perlmutter, Naren Ramakrishna, Eric P. Winer, and Nancy E. Davidson

ABSTRACT

Purpose

To update evidence-based guideline recommendations for practicing oncologists and others on systemic therapy for patients with human epidermal growth factor receptor 2 (HER2)–positive advanced breast cancer to 2018.

Methods

An Expert Panel conducted a targeted systematic literature review (for both systemic treatment and CNS metastases) and identified 622 articles. Outcomes of interest included overall survival, progression-free survival, and adverse events.

Results

Of the 622 publications identified and reviewed, no additional evidence was identified that would warrant a change to the 2014 recommendations.

Recommendations

HER2-targeted therapy is recommended for patients with HER2-positive advanced breast cancer, except for those with clinical congestive heart failure or significantly compromised left ventricular ejection fraction, who should be evaluated on a case-by-case basis. Trastuzumab, pertuzumab, and taxane for first-line treatment and trastuzumab emtansine for second-line treatment are recommended. In the third-line setting, clinicians should offer other HER2-targeted therapy combinations or trastuzumab emtansine (if not previously administered) and may offer pertuzumab if the patient has not previously received it. Optimal duration of chemotherapy is at least 4 to 6 months or until maximum response, depending on toxicity and in the absence of progression. HER2-targeted therapy can continue until time of progression or unacceptable toxicities. For patients with HER2-positive and estrogen receptor–positive/progesterone receptor–positive breast cancer, clinicians may recommend either standard first-line therapy or, for selected patients, endocrine therapy plus HER2-targeted therapy or endocrine therapy alone. Additional information is available at www.asco.org/breast-cancer-guidelines.

J Clin Oncol 36:2736-2740. © 2018 by American Society of Clinical Oncology

INTRODUCTION

The goal of this update is to provide oncologists, other health care practitioners, patients, and caregivers with recommendations regarding guidance for optimal management of patients with HER2-positive metastatic breast cancer.

ASCO first published two evidence-based clinical practice guidelines on optimal management of patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer in 2014.^{1,2} The goal of this 2018 guideline update is to provide oncologists and other clinicians

with current recommendations regarding the treatment of patients with HER2-positive metastatic breast cancer. The current 2018 update assesses whether the 2014 recommendations remain valid. A complete list of previous recommendations is available at www.asco.org/breast-cancer-guidelines and in Data Supplement 1.

METHODS

Guideline Update Process

ASCO uses a “signals”³ approach to facilitate guideline updating. This approach is intended to identify new,

Author affiliations and support information (if applicable) appear at the end of this article.

Published at jco.org on June 25, 2018.

S.H.G. and N.E.D. were Expert Panel co-chairs.

Clinical Practice Guideline Committee approval: April 4, 2018.

Editor's note: This American Society of Clinical Oncology (ASCO) 2018 Clinical Practice Guideline update reaffirms and summarizes the recommendations that were previously published in 2014; the 2014 recommendations remain current as of April 2018. Additional information, including an abbreviated Data Supplement with new studies, a Methodology Supplement, slide sets, clinical tools and resources, and links to patient information at www.cancer.net, is available at www.asco.org/breast-cancer-guidelines.


Reprint requests: 2318 Mill Rd, Suite 800, Alexandria, VA 22314; e-mail: guidelines@asco.org.


Corresponding author: American Society of Clinical Oncology, 2318 Mill Rd, Suite 800, Alexandria, VA 22314; e-mail: guidelines@asco.org.

© 2018 by American Society of Clinical Oncology

0732-183X/18/3626w-2736w/\$20.00

ASSOCIATED CONTENT

 Appendix
DOI: <https://doi.org/10.1200/JCO.2018.79.2697>

 Data Supplement
DOI: <https://doi.org/10.1200/JCO.2018.79.2697>

DOI: <https://doi.org/10.1200/JCO.2018.79.2697>

THE BOTTOM LINE

Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: ASCO Clinical Practice Guideline Update**Guideline Question**

What is the optimal medical therapy for advanced human epidermal growth factor receptor 2 (HER2)–positive breast cancer, specifically HER2-targeted therapy, either alone or in combination with chemotherapy and/or endocrine therapy?

Target Population

Individuals with advanced HER2-positive breast cancer

Target Audience

Medical oncologists, radiation oncologists, surgeons, oncology nurses, and patients/caregivers

Methods

A systematic review of the literature was performed and relevant evidence was evaluated for inclusion into this updated clinical practice guideline using the signals approach.

Recommendations

- Clinicians should recommend HER2-targeted therapy–based combinations for first-line treatment, except for highly selected patients with estrogen receptor–positive or progesterone receptor–positive and HER2-positive disease, for whom clinicians may use endocrine therapy alone (Type: evidence based; Evidence quality: high; Strength of recommendation: strong).
 - If a patient’s HER2-positive advanced breast cancer has progressed during or after first-line HER2-targeted therapy, clinicians should recommend second-line HER2-targeted therapy–based treatment (Type: evidence based; Evidence quality: high; Strength of recommendation: strong).
 - If a patient’s HER2-positive advanced breast cancer has progressed during or after second-line or greater HER2-targeted treatment, clinicians should recommend third-line or greater HER2-targeted therapy–based treatment (Type: evidence based; Evidence quality: intermediate; Strength of recommendation: moderate).
 - Clinicians should recommend the combination of trastuzumab, pertuzumab, and a taxane for first-line treatment, unless the patient has a contraindication to taxanes (Type: evidence based; Evidence quality: high; Strength of recommendation: strong).
 - If a patient’s HER2-positive advanced breast cancer has progressed during or after first-line HER2-targeted therapy, clinicians should recommend trastuzumab emtansine (T-DM1) as second-line treatment (Type: evidence based; Evidence quality: high; Strength of recommendation: strong).
 - If a patient’s HER2-positive advanced breast cancer has progressed during or after second-line or greater HER2-targeted therapy, but she has not received T-DM1, clinicians should offer T-DM1 (Type: evidence based; Evidence quality: high; Strength of recommendation: strong).
 - If a patient’s HER2-positive advanced breast cancer has progressed during or after second-line or greater HER2-targeted treatment, but she has not received pertuzumab, clinicians may offer pertuzumab (Type: informal consensus; Evidence quality: insufficient; Strength of recommendation: weak).
 - If a patient’s HER2-positive advanced breast cancer has progressed during or after second-line or greater HER2-targeted treatment, and she has already received pertuzumab and T-DM1, clinicians should recommend third-line or greater HER2-targeted therapy–based treatment. Options include lapatinib plus capecitabine, as well as other combinations of chemotherapy, and trastuzumab, lapatinib and trastuzumab, or hormonal therapy (in patients with estrogen
- (continued on following page)

THE BOTTOM LINE (CONTINUED)

receptor–positive and/or progesterone receptor–positive disease). There is insufficient evidence to recommend one regimen over another (Type: informal consensus; Evidence quality: insufficient; Strength of recommendation: weak).

- If a patient is receiving HER2-targeted therapy and chemotherapy combinations, the chemotherapy should continue for approximately 4 to 6 months (or longer) and/or to the time of maximal response, depending on toxicity and in the absence of progression. When chemotherapy is stopped, clinicians should continue the HER2-targeted therapy; no further change in the regimen is needed until the time of progression or unacceptable toxicities (Type: evidence based; Evidence quality: intermediate; Strength of recommendation: moderate).
- If a patient finished trastuzumab-based adjuvant treatment \leq 12 months before recurrence, clinicians should follow the second-line HER2-targeted therapy–based treatment recommendations (Type: evidence based; Evidence quality: intermediate; Strength of recommendation: moderate).
- If a patient finished trastuzumab-based adjuvant treatment $>$ 12 months before recurrence, clinicians should follow the first-line HER2-targeted therapy–based treatment recommendations (Type: evidence based; Evidence quality: high; Strength of recommendation: strong).
- If a patient's cancer is hormone receptor positive and HER2 positive, clinicians may recommend either:
 - HER2-targeted therapy plus chemotherapy (Type: evidence based; Evidence quality: high; Strength of recommendation: strong).
 - Endocrine therapy plus trastuzumab or lapatinib (in selected cases; Type: evidence based; Evidence quality: high; Strength of recommendation: moderate).
 - Endocrine therapy alone (in selected cases; Type: evidence based; Evidence quality: intermediate; Strength of recommendation: weak).
- If a patient has started with an HER2-positive targeted therapy and chemotherapy combination, clinicians may add endocrine therapy to the HER2-targeted therapy when chemotherapy ends and/or when the cancer progresses (Type: informal consensus; Evidence quality: insufficient; Strength of recommendation: weak).
- In special circumstances, such as low disease burden, presence of comorbidities (contradictions to HER2-targeted therapy such as congestive heart failure), and/or presence of a long disease-free interval, clinicians may offer first-line endocrine therapy alone (Type: informal consensus; Evidence quality: intermediate; Strength of recommendation: weak).

Qualifying statement: Although clinicians may discuss using endocrine therapy with or without HER2-targeted therapy, the majority of patients will still receive chemotherapy plus HER2-targeted therapy.

Note: The guide for rating recommendations and evidence quality is provided in the Methodology Supplement.

Additional Resources

More information, including a Data Supplement with additional evidence tables, a Methodology Supplement with information about evidence quality and strength of recommendations, slide sets, and clinical tools and resources, is available at www.asco.org/breast-cancer-guidelines. Patient information is available at www.cancer.net

ASCO believes that cancer clinical trials are vital to inform medical decisions and improve cancer care, and that all patients should have the opportunity to participate.

potentially practice-changing data—signals—that might translate into revised practice recommendations. The approach relies on routine literature searching and the expertise of ASCO Guideline Panel members to identify signals. The Methodology Supplement available at www.asco.org/breast-cancer-guidelines provides additional information about the signals approach.

PubMed and the Cochrane Library were searched for randomized controlled trials, systematic reviews, meta-analyses, and clinical practice guidelines for the period from October 4, 2011, to overlap with the search

for the previous guideline, through August 11, 2017. The disease and intervention search terms were those that were used for the 2014 guideline. An Expert Panel (members listed in Appendix Table A1, online only), formed in accordance with the ASCO Conflict of Interest Management Procedures for Clinical Practice Guidelines, reviewed the abstracts that were identified for predefined signals that would suggest the need to change a previous recommendation. Additional information about the results of the updated literature search (Data Supplement 2) and 2017

search strategy string and results (Data Supplement 3), as well as a discussion of the ASCO signals approach to guideline updating, are available at www.asco.org/breast-cancer-guidelines and in the 2018 Data Supplement and 2018 Methodology Supplement, respectively. A Quality of Reporting of Meta-Analyses diagram of the updated search and the clinical questions are provided in Data Supplements 4 and 5, respectively.

The Expert Panel communicated via telephone and e-mail to consider the evidence for each of the 2018 recommendations. This systematic review–based guideline product was developed by a multidisciplinary Expert Panel, which included patient representatives and an ASCO guidelines staff member with health research methodology expertise. The guideline was circulated in draft form to the Expert Panel. ASCO's Clinical Practice Guidelines Committee leadership reviewed and approved the final document. All funding for the administration of the project was provided by ASCO.

Guideline Disclaimer. The Clinical Practice Guidelines and other guidance published herein are provided by the American Society of Clinical Oncology, Inc. (ASCO) to assist providers in clinical decision making. The information herein should not be relied upon as being complete or accurate, nor should it be considered as inclusive of all proper treatments or methods of care or as a statement of the standard of care. With the rapid development of scientific knowledge, new evidence may emerge between the time information is developed and when it is published or read. The information is not continually updated and may not reflect the most recent evidence. The information addresses only the topics specifically identified therein and is not applicable to other interventions, diseases, or stages of diseases. This information does not mandate any particular course of medical care. Further, the information is not intended to substitute for the independent professional judgment of the treating provider, as the information does not account for individual variation among patients. Recommendations reflect high, moderate, or low confidence that the recommendation reflects the net effect of a given course of action. The use of words like “must,” “must not,” “should,” and “should not” indicates that a course of action is recommended or not recommended for either most or many patients, but there is latitude for the treating physician to select other courses of action in individual cases. In all cases, the selected course of action should be considered by the treating provider in the context of treating the individual patient. Use of the information is voluntary. ASCO provides this information on an “as is” basis and makes no warranty, express or implied, regarding the information. ASCO specifically disclaims any warranties of merchantability or fitness for a particular use or purpose. ASCO assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of this information, or for any errors or omissions.

This is the most recent information as of the publication date. For the most recent information, and to submit new evidence, please visit www.asco.org/breast-cancer-guidelines.

Guideline and Conflicts of Interest. The Expert Panel was assembled in accordance with ASCO's Conflict of Interest Policy Implementation for Clinical Practice Guidelines (“Policy,” found at <http://www.asco.org/rwc>). All members of the Expert Panel completed ASCO's disclosure form, which requires disclosure of financial and other interests, including relationships with commercial entities that are reasonably likely to experience direct regulatory or commercial impact as a result of promulgation of the guideline. Categories for disclosure include employment; leadership; stock or other ownership; honoraria, consulting or advisory role; speaker's bureau; research funding; patents, royalties, other intellectual property; expert testimony; travel, accommodations, expenses; and other relationships. In accordance with the Policy, the majority of the members of the Expert Panel did not disclose any relationships constituting a conflict under the Policy.

RESULTS

A joint search for both guidelines yielded 622 publications. After careful review of the identified publications, the Expert Panel

concluded that there were no results that would change the 2014 guideline recommendations.¹ A bibliography of the results of the updated literature search is provided in Data Supplement 2.

RECOMMENDATIONS

The 2018 recommendations are listed in the Bottom Line Box. These recommendations are consistent with the previous (2014) recommendations.

ASCO believes that cancer clinical trials are vital to inform medical decisions and improve cancer care, and that all patients should have the opportunity to participate.

ADDITIONAL RESOURCES

More information, including Data and Methodology Supplements, slide sets, and clinical tools and resources, is available at www.asco.org/breast-cancer-guidelines. Patient information is available at www.cancer.net.

Related ASCO Guidelines

- Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases⁴ (<http://ascopubs.org/doi/10.1200/JCO.2018.79.2713>)
- Integration of Palliative Care into Standard Oncology Practice⁵ (<http://ascopubs.org/doi/10.1200/JCO.2016.70.1474>)
- Patient-Clinician Communication⁶ (<http://ascopubs.org/doi/10.1200/JCO.2017.75.2311>)
- American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care⁷ (<http://ascopubs.org/doi/10.1200/JCO.2015.64.3809>)

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Disclosures provided by the authors are available with this article at jco.org.

AUTHOR CONTRIBUTIONS

Administrative support: Sarah Temin

Manuscript writing: All authors

Final approval of manuscript: All authors

REFERENCES

1. Giordano SH, Temin S, Kirshner JJ, et al: Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. *J Clin Oncol* 32:2078-2099, 2014
2. Ramakrishna N, Temin S, Chandralapaty S, et al: Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: ASCO clinical practice guideline update. *J Clin Oncol* doi:10.1200/JCO.2018.79.2713
3. Shojania KG, Sampson M, Ansari MT, et al: How quickly do systematic reviews go out of date? A survival analysis. *Ann Intern Med* 147:224-233, 2007
4. Ramakrishna N, Temin S, Chandralapaty S, et al: Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: ASCO clinical practice guideline update. *J Clin Oncol* doi:10.1200/JCO.2018.79.2713
5. Ferrell BR, Temel JS, Temin S, et al: Integration of palliative care into standard oncology care: American Society of Clinical Oncology clinical practice guideline update. *J Clin Oncol* 35:96-112, 2017
6. Gilligan T, Coyle N, Frankel RM, et al: Patient-clinician communication: American Society of Clinical Oncology consensus guideline. *J Clin Oncol* 35:3618-3632, 2017
7. Runowicz CD, Leach CR, Henry NL, et al: American Cancer Society/American Society of Clinical Oncology breast cancer survivorship care guideline. *J Clin Oncol* 34:611-635, 2016

Affiliations

Sharon H. Giordano, The University of Texas MD Anderson, Houston; **Debra A. Patt**, Texas Oncology, Austin, TX; **Sarah Temin**, American Society of Clinical Oncology, Alexandria, VA; **Sarat Chandralapaty** and **Shanu Modi**, Memorial Sloan Kettering Cancer Center; **Francisco J. Esteva**, New York University Langone Medical Center, New York; **Jeffrey J. Kirshner**, Hematology/Oncology Associates of Central New York, East Syracuse, NY; **Jennie R. Crews**, Seattle Cancer Care Alliance; **Nancy E. Davidson**, Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA; **Ian E. Krop**, **Nancy U. Lin**, and **Eric P. Winer**, Dana-Farber Cancer Institute, Boston, MA; **Jennifer Levinson**, Ponte Vedra Beach; **Naren Ramakrishna**, Orlando Health University of Florida Health Cancer Center, Orlando, FL; and **Jane Perlmutter**, Ann Arbor, MI.

ASCO's Year-Round Member Referral Campaign

ASCO members: Your personal referral conveys more to a prospective member than any ad or brochure ever could. The Member Referral Campaign is our way of saying "thank you" for sharing the value of ASCO membership with your colleagues.

How to refer: Simply provide your nonmember colleagues with your ASCO ID number for them to enter with their membership application at join.asco.org, and begin earning credit!

At the end of the annual cycle, you will receive credit for the total number of referrals you have made:

- Refer two new members and receive a \$10 credit
- Refer five new members and receive a \$50 credit
- Refer 10 new members and receive a \$100 credit

Not an ASCO member? Earn your ASCO member colleagues credit for referring you when you complete the membership application at join.asco.org. Once you are inducted, you can begin earning credit for your own referrals!

ASCO[®]
AMERICAN SOCIETY OF CLINICAL ONCOLOGY

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: ASCO Clinical Practice Guideline Update

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/site/ifc.

Sharon H. Giordano

No relationship to disclose

Sarah Temin

No relationship to disclose

Sarat Chandarlapaty

Honoraria: Chugai Pharma, AstraZeneca, Sermonix Pharmaceuticals, MacroGenics, Agendia, Novartis, Context Therapeutics

Research Funding: Novartis (Inst)

Travel, Accommodations, Expenses: MacroGenics, AstraZeneca, Novartis

Jennie R. Crews

No relationship to disclose

Francisco J. Esteva

Consulting or Advisory Role: Genentech, Roche, Novartis, Celgene, NanoString Technologies, Celltrion, AstraZeneca, Glenmark Pharmaceuticals, Puma Biotechnology, Seattle Genetics

Research Funding: Novartis (Inst), Kadmon Holdings (Inst), Merrimack Pharmaceuticals (Inst), Synta (Inst), Genentech (Inst), Roche (Inst)

Patents, Royalties, Other Intellectual Property: Myriad Genetics (royalties)

Travel, Accommodations, Expenses: Novartis

Jeffrey J. Kirshner

Consulting or Advisory Role: AstraZeneca

Ian E. Krop

Employment: AMAG Pharmaceuticals (I)

Leadership: AMAG Pharmaceuticals (I)

Stock or Other Ownership: AMAG Pharmaceuticals (I)

Honoraria: Genentech, Roche

Consulting or Advisory Role: Genentech, Roche, Seattle Genetics, Daiichi Sankyo, MacroGenics

Research Funding: Genentech

Jennifer Levinson

No relationship to disclose

Nancy U. Lin

Research Funding: Genentech, Cascadian Therapeutics

Patents, Royalties, Other Intellectual Property: Royalties for chapter in UpToDate regarding management of breast cancer brain metastases

Shanu Modi

Speakers' Bureau: Genentech

Research Funding: Roche, Genentech, Novartis, Seattle Genetics, Synta, Daiichi Sankyo

Debra A. Patt

Employment: Texas Oncology, McKesson, MEDNAX (I)

Leadership: McKesson, MEDNAX (I), Texas Oncology

Stock or Other Ownership: MEDNAX (I)

Travel, Accommodations, Expenses: McKesson

Jane Perlmutter

No relationship to disclose

Naren Ramakrishna

Stock or Other Ownership: Cytecare Cancer Center

Eric P. Winer

Honoraria: Genentech, Roche, TESARO, Eli Lilly

Consulting or Advisory Role: Leap Therapeutics, InfiniteMD

Research Funding: Genentech (Inst)

Nancy E. Davidson

No relationship to disclose

Acknowledgment

The Expert Panel thanks the Clinical Practice Guidelines Committee for its thoughtful reviews and insightful comments on this guideline.

Appendix**Table A1.** Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer Expert Panel Membership

Name (and Designation)	Affiliation/Institution	Role/Area of Expertise
Nancy E. Davidson, MD, co-chair	Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA	Medical oncology
Sharon H. Giordano, MD, co-chair	The University of Texas MD Anderson Cancer Center, Houston, TX	Medical oncology
Sarat Chandarlapaty, MD, PhD	Memorial Sloan Kettering Cancer Center, New York, NY	Medical oncology
Jennie R. Crews, MD	Seattle Cancer Care Alliance, Seattle, WA	Medical oncology PGIN representative
Francisco J. Esteva, MD, PhD	New York University Langone Medical Center, Perlmutter Cancer Center, New York, NY	Medical oncology
Jeffrey J. Kirshner, MD	Hematology Oncology Associates of Central New York, East Syracuse, NY	Medical oncology
Ian E. Krop, MD, PhD	Dana-Farber Cancer Institute, Boston, MA	Medical oncology
Jennifer Levinson	Ponte Vedra Beach, FL	Patient representative
Nancy U. Lin, MD	Dana-Farber Cancer Institute, Boston, MA	Medical oncology
Shanu Modi, MD	Memorial Sloan Kettering Cancer Center, New York, NY	Medical oncology
Debra A. Patt, MD, MPH, MBA	Texas Oncology, Austin, TX	Medical oncology
Jane Perlmutter, PhD	Ann Arbor, MI	Patient representative
Naren Ramakrishna, MD, PhD	Orlando Health University of Florida Cancer Center, Orlando, FL	Radiation oncology
Eric P. Winer, MD	Dana-Farber Cancer Institute, Boston, MA	Medical oncology
Sarah Temin, MSPH	ASCO	Staff/health research methodologist

Abbreviation: PGIN, Practice Guidelines Implementation Network.